Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents

Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison... CNS Drugs https://doi.org/10.1007/s40263-018-0531-7 CORRECTION Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents 1 1 Michael W. Jann Scott R. Penzak Springer International Publishing AG, part of Springer Nature 2018 Correction to: CNS Drugs (2018) 32 (3): 241–257 experienced acute exacerbations and in patients who https://doi.org/10.1007/s40263-018-0508-6 required maintenance treatment [21, 45, 46]. 3. On Page 246, under Paliperidone Palmitate, column 2— 1. On Page 244, under General Pharmacokinetic Principles, the text that read: Column 1—the following sentence should come after ref- The pharmacokinetics of 3MPP were characterized in a erence 21: single-dose study in which patients received doses ranging ‘‘Doses of intramuscular paliperidone palmitate can be from 75 to 525 mg (819 mg) [30]. conveyed in mg of paliperidone palmitate or as mg Should read as: equivalents of paliperidone (active moiety, mg eq). For example, 156 mg of intramuscular paliperidone palmitate The pharmacokinetics of 3MPP were characterized in a is equivalent to 100 mg of paliperidone per mL of aqueous single-dose study in which patients received doses ranging suspension [11, 21]. In this article, we present doses of from 75 to 525 mg [32]. intramuscular paliperidone palmitate in mg, i.e. ‘75 mg’ 4. On Page 246, under Paliperidone Palmitate, column 2— refers to 75 mg eq of paliperidone, which is equivalent to the text that read: 117 mg of paliperidone palmitate.’’ In a randomized multicenter clinical trial, 506 patients with 2. On Page 246, under Paliperidone Palmitate column 2— schizophrenia received 3MPP in four phases: (1) screening, the text that read: (2) 1MPP treatment for 17 weeks, (3) 3MPP single-dose The efficacy and safety of 1MPP has been established in administration, and (4) double-blind randomization of patients with schizophrenia who experience acute exacerba- drug-versus-placebo (1:1) [48]. tions and in patients requiring maintenance treatment [45, 46]. Should read as: Should read as: In a randomized, multicentre, multi-phase clinical trial, patients The efficacy and safety of 1MPP was established for reg- with schizophrenia received 1MPP treatment for 17 weeks ulatory approval in patients with schizophrenia who (n = 506) followed by a single dose of 3MPP (n = 379) and then entered a double-blind randomization drug-versus-pla- cebo phase (n = 160 vs 145, respectively) [48]. The original article can be found online at https://doi.org/10.1007/ s40263-018-0508-6. 5. On Page 246, under Paliperidone Palmitate, column 2—reference to Table 2 should be removed from the text & Michael W. Jann Michael.jann@unthsc.edu that reads: A dosing conversion factor of 3.5 was used when switching Department of Pharmacotherapy, University of North Texas System College of Pharmacy (UNTSCP), University of North patients from 1MPP to 3MPP based on 1MPP and 3MPP Texas Health Science Center (UNTHSC), 3500 Camp Bowie pharmacokinetic profiles. Blvd., Fort Worth, TX 76107, USA http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CNS Drugs Springer Journals

Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/correction-to-long-acting-injectable-second-generation-antipsychotics-EU1ikWtbmd
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Neurology; Psychopharmacology; Pharmacotherapy; Neurosciences; Psychiatry
ISSN
1172-7047
eISSN
1179-1934
D.O.I.
10.1007/s40263-018-0531-7
Publisher site
See Article on Publisher Site

Abstract

CNS Drugs https://doi.org/10.1007/s40263-018-0531-7 CORRECTION Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents 1 1 Michael W. Jann Scott R. Penzak Springer International Publishing AG, part of Springer Nature 2018 Correction to: CNS Drugs (2018) 32 (3): 241–257 experienced acute exacerbations and in patients who https://doi.org/10.1007/s40263-018-0508-6 required maintenance treatment [21, 45, 46]. 3. On Page 246, under Paliperidone Palmitate, column 2— 1. On Page 244, under General Pharmacokinetic Principles, the text that read: Column 1—the following sentence should come after ref- The pharmacokinetics of 3MPP were characterized in a erence 21: single-dose study in which patients received doses ranging ‘‘Doses of intramuscular paliperidone palmitate can be from 75 to 525 mg (819 mg) [30]. conveyed in mg of paliperidone palmitate or as mg Should read as: equivalents of paliperidone (active moiety, mg eq). For example, 156 mg of intramuscular paliperidone palmitate The pharmacokinetics of 3MPP were characterized in a is equivalent to 100 mg of paliperidone per mL of aqueous single-dose study in which patients received doses ranging suspension [11, 21]. In this article, we present doses of from 75 to 525 mg [32]. intramuscular paliperidone palmitate in mg, i.e. ‘75 mg’ 4. On Page 246, under Paliperidone Palmitate, column 2— refers to 75 mg eq of paliperidone, which is equivalent to the text that read: 117 mg of paliperidone palmitate.’’ In a randomized multicenter clinical trial, 506 patients with 2. On Page 246, under Paliperidone Palmitate column 2— schizophrenia received 3MPP in four phases: (1) screening, the text that read: (2) 1MPP treatment for 17 weeks, (3) 3MPP single-dose The efficacy and safety of 1MPP has been established in administration, and (4) double-blind randomization of patients with schizophrenia who experience acute exacerba- drug-versus-placebo (1:1) [48]. tions and in patients requiring maintenance treatment [45, 46]. Should read as: Should read as: In a randomized, multicentre, multi-phase clinical trial, patients The efficacy and safety of 1MPP was established for reg- with schizophrenia received 1MPP treatment for 17 weeks ulatory approval in patients with schizophrenia who (n = 506) followed by a single dose of 3MPP (n = 379) and then entered a double-blind randomization drug-versus-pla- cebo phase (n = 160 vs 145, respectively) [48]. The original article can be found online at https://doi.org/10.1007/ s40263-018-0508-6. 5. On Page 246, under Paliperidone Palmitate, column 2—reference to Table 2 should be removed from the text & Michael W. Jann Michael.jann@unthsc.edu that reads: A dosing conversion factor of 3.5 was used when switching Department of Pharmacotherapy, University of North Texas System College of Pharmacy (UNTSCP), University of North patients from 1MPP to 3MPP based on 1MPP and 3MPP Texas Health Science Center (UNTHSC), 3500 Camp Bowie pharmacokinetic profiles. Blvd., Fort Worth, TX 76107, USA

Journal

CNS DrugsSpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off